Summit Therapeutics Inc.
SMMT
$16.18
$0.060.34%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 556.75M | 493.35M | 410.89M | 64.28M | 60.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.09B | 935.11M | 759.28M | 235.45M | 210.99M |
| Operating Income | -1.09B | -935.11M | -759.28M | -235.45M | -210.99M |
| Income Before Tax | -1.08B | -921.62M | -746.08M | -240.76M | -221.32M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.08K | -921.62 | -746.08 | -240.76 | -221.32 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.08B | -921.62M | -746.08M | -240.76M | -221.32M |
| EBIT | -1.09B | -935.11M | -759.28M | -235.45M | -210.99M |
| EBITDA | -1.09B | -934.99M | -759.18M | -235.37M | -210.90M |
| EPS Basic | -1.44 | -1.24 | -1.01 | -0.33 | -0.31 |
| Normalized Basic EPS | -0.90 | -0.78 | -0.63 | -0.19 | -0.18 |
| EPS Diluted | -1.45 | -1.25 | -1.02 | -0.35 | -0.32 |
| Normalized Diluted EPS | -0.90 | -0.78 | -0.63 | -0.19 | -0.18 |
| Average Basic Shares Outstanding | 2.99B | 2.96B | 2.94B | 2.91B | 2.87B |
| Average Diluted Shares Outstanding | 2.99B | 2.96B | 2.94B | 2.91B | 2.87B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |